2011
DOI: 10.2967/jnumed.111.096578
|View full text |Cite
|
Sign up to set email alerts
|

Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

7
165
0
1

Year Published

2013
2013
2020
2020

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 253 publications
(175 citation statements)
references
References 90 publications
7
165
0
1
Order By: Relevance
“…Ki-67 played no role in 18 F-FDG uptake. 18 F-FDG is an analogue of glucose and uses a similar transport system as glucose (Bohnen et al, 2012). In tumor cells, especially malignant tumor cells from lung cancer (Liao et al, 2012), breast cancer (Groheux et al, 2011) and NHL (Alongi et al, 2014;Singh et al, 2014), 18 F-FDG accumulation rises dramatically.…”
Section: Discussionmentioning
confidence: 99%
“…Ki-67 played no role in 18 F-FDG uptake. 18 F-FDG is an analogue of glucose and uses a similar transport system as glucose (Bohnen et al, 2012). In tumor cells, especially malignant tumor cells from lung cancer (Liao et al, 2012), breast cancer (Groheux et al, 2011) and NHL (Alongi et al, 2014;Singh et al, 2014), 18 F-FDG accumulation rises dramatically.…”
Section: Discussionmentioning
confidence: 99%
“…Diagnosis of bvFTD remains difficult, with patients being erroneously diagnosed with Alzheimer's disease (AD) or psychiatric disorders 5, 6, 7. A large body of work has demonstrated that brain imaging, in particular structural magnetic resonance imaging (MRI) and functional imaging of cerebral blood flow (CBF) with SPECT or cerebral metabolic rate of glucose (CMRgl) with fluorodeoxyglucose (FDG) positron emission tomography (PET), can improve the accuracy of differential diagnosis in bvFTD 8, 9, 10, 11, 12, 13, 14, 15, 16, 17. These findings led the Center for Medicare and Medicaid Services (CMS) to approve FDG‐PET as a diagnostic test for differentiating bvFTD from AD (https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=288&ncdver=3&bc=BAABAAAAAAAA&).…”
Section: Introductionmentioning
confidence: 99%
“…2 In contrast, positron emission tomography with [ 18 F]-fluorodeoxyglucose (FDG-PET) is an established clinical tool, assisting early and differential diagnosis of dementing and movement disorders. [3][4][5] These conditions are accompanied by a certain spatial pattern of neural degeneration that is captured by PET as regional glucose hypometabolism. So far, however, this imaging tool has got little attention in studies of healthy cognitive function and non-degenerative brain diseases.…”
Section: Introductionmentioning
confidence: 99%